Hot Features
Neurogene Inc., a clinical stage biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 that is packaged in an adeno-associated virus 9, which is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a... Neurogene Inc., a clinical stage biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 that is packaged in an adeno-associated virus 9, which is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease. It has a license agreement with The University of Edinburgh, Virovek, Inc., Sigma-Aldrich Co. LLC., and Leland Stanford Junior University. The company was founded in 2018 and is headquartered in New York, New York. Show more
| Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -1.09 | -3.95213923133 | 27.58 | 28.81 | 25.76 | 88407 | 27.10996561 | CS |
| 4 | -3.98 | -13.0620282245 | 30.47 | 33.9899 | 25.76 | 118296 | 28.54851517 | CS |
| 12 | 4.19 | 18.7892376682 | 22.3 | 33.9899 | 18.23 | 148765 | 25.31721457 | CS |
| 26 | 5.31 | 25.0708215297 | 21.18 | 33.9899 | 15.93 | 156616 | 22.3457198 | CS |
| 52 | 4.87 | 22.525439408 | 21.62 | 37.265899 | 14.65 | 177089 | 22.70761522 | CS |
| 156 | 11.92 | 81.8119423473 | 14.57 | 74.49 | 6.875 | 191837 | 25.56215416 | CS |
| 260 | 11.92 | 81.8119423473 | 14.57 | 74.49 | 6.875 | 191837 | 25.56215416 | CS |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
Vous avez déjà un compte? Connexion
Vous n'avez pas de compte ? Inscription
En m'inscrivant, je confirme avoir lu, compris et accepté les Conditions générales d'ADVFN et j'affirme etre un investisseur privé.